Pharmaceuticals Pricing Board (HILA), Finnish Medicines Agency (Fimea), Social Insurance Institution (KELA) and Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) organize a hearing on methods used for Health Technology Assessment (HTA) on Friday December 9th 2022. In the event, the developers are given an opportunity to present their methods potentially used in the upcoming reimbursement submissions or appraisals to Finnish authorities involved in HTA. The methods to be presented include, but are not limited to:
- Indirect treatment comparisons
- Real world evidence on effectiveness and costs of concurrent treatments or consequences of adapting a new treatment alternative
- Measuring health-related quality of life
- Extrapolation of clinical trials
- Methods and software for cost-effectiveness modelingPharmaceuticals Pricing Board (HILA), Finnish Medicines Agency (Fimea), Social Insurance Institution (KELA) and Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) organize a hearing on methods used for Health Technology Assessment (HTA) on Friday December 9th 2022. In the event, the developers are given an opportunity to present their methods potentially used in the upcoming reimbursement submissions or appraisals to Finnish authorities involved in HTA. The methods to be presented include, but are not limited to:
- Indirect treatment comparisons
- Real world evidence on effectiveness and costs of concurrent treatments or consequences of adapting a new treatment alternative
- Measuring health-related quality of life
- Extrapolation of clinical trials
- Methods and software for cost-effectiveness modeling
The hearing is not meant for discussing or giving advice on preparing reimbursement applications or appraisals. The participants may use simulated data, or alternatively when using actual data make sure acquire necessary permits. Discussion will be academic and any feedback that the authorities may provide on the strength and weaknesses of the model are their personal opinions, which may not be cited later when the method is applied in the actual HTA process.
Parties such as pharmaceutical companies, consultancies or universities interested in the hearing are encouraged to register by email to kalle.aaltonen@gov.fi by October 14th 2022. A short summary of the topic as well as the presenters’ names and affiliation. In addition, the presenter candidates should disclose whether they arrive to Helsinki or Kuopio, or if they give the presentation via Teams. The parties chosen to present will be announced by October 28th 2022.
The hearing takes place on Friday December 9th 2022 starting at 9.00 am. Each presentation lasts 90 minutes including the discussion. A total of three presentations have been scheduled. Should there be more registrations than the number of presentations available, the ones with highest relevance and urgency to Finnish HTA system will be selected. The presenters electing to give a face-to-face presentation, are instructed to arrive at the premises of either Hila (Etelä-Esplanadi 4, 00130 Helsinki) or Fimea Microkatu 1, 70210 Kuopio) at the scheduled time.